# Mortality Trends in the United States due to Concurrent Heart Failure, Atrial Fibrillation/Flutter and Sepsis

**Authors:** Gaithrri Shanmuganathan, Nicole Jeongha Lee, Devendra K Agrawal

PMC · DOI: 10.26502/fccm.92920482 · Cardiology and cardiovascular medicine · 2026-04-01

## TL;DR

Mortality from heart failure, atrial fibrillation/flutter, and sepsis doubled in the U.S. from 1999 to 2023, with increasing rates among specific demographics and regions.

## Contribution

This study identifies accelerating mortality trends linked to concurrent heart failure, AF/AFL, and sepsis, highlighting demographic and geographic disparities.

## Key findings

- Mortality rates doubled from 1999 to 2020, with a significant acceleration after 2012.
- White males in middle age and the Midwest/South regions experienced the highest increases in mortality.
- Post-pandemic mortality trends (2018–2023) continued to rise without stabilization.

## Abstract

Heart failure (HF), atrial fibrillation (AF)/atrial flutter (AFL) and sepsis commonly co-occur in hospitalized patients. This study determines temporal mortality trends associated with concurrent HF, AF/AFL, and sepsis among adults across demographic and geographic groups in the United States. The CDC Wonder database was utilized to extract age-adjusted mortality rates (AAMR) per 100,000 for deaths listing HF, AF/AFL, and sepsis. Trends were analyzed by age, race/ethnicity, region, and sex. Joinpoint regression calculated the annual percent change (APC) and average annual percent change (AAPC) for AAMR with 95% CI. From 1999 to 2023, there were 1,749,565 deaths involving HF, AF/AFL, and sepsis. AAMR doubled (1999: 11.79 vs. 2020: 23.87 per 100,000), with a critical 2012 inflection point accelerating mortality from 1.29% to 6.42% annually. White individuals had steepest post-2012 acceleration (6.67%), surpassing Black individuals by 2020 (24.88 vs. 20.80 per 100,000). Males had higher AAMRs than females (28.69 vs 20.19 per 100,000 in 2020). Middle-aged adults (45-64 years) showed highest acceleration (9.98-10.30%), nearly double those aged ≥85 years (5.82%). The Midwest and South had steepest increases (7.07% and 7.11%). During 2018–2023, mortality continued increasing at 6.11% annually without stabilization. Mortality involving HF, AF/AFL and sepsis doubled from 1999–2023 with sustained acceleration and no post-pandemic stabilization. Targeted interventions should focus on males, middle-aged adults, and high-risk regions with enhanced post-discharge care.

## Linked entities

- **Diseases:** Heart failure (MONDO:0005252), Atrial fibrillation (MONDO:0004981), Atrial flutter (MONDO:0005310)

## Full-text entities

- **Diseases:** arrhythmia (MESH:D001145), renal failure (MESH:D051437), venous congestion (MESH:D006940), inflammation (MESH:D007249), hypertensive heart and renal disease (MESH:D006977), streptococcal sepsis (MESH:D013290), ischemic heart disease (MESH:D017202), COVID-19 (MESH:D000086382), bowel edema (MESH:D004487), lymphatic dysregulation (MESH:D008206), HF (MESH:D006333), hypertensive heart disease (MESH:D006973), fibrosis (MESH:D005355), Cancer (MESH:D009369), Sepsis (MESH:D018805), AF (MESH:D001281), diabetes (MESH:D003920), mitochondrial dysfunction (MESH:D028361), cardiomyopathy (MESH:D009202), tachycardia (MESH:D013610), AFL (MESH:D001282), cardiovascular (MESH:D002318), APC (MESH:D009402), AAMR (MESH:D003643), obesity (MESH:D009765), impaired immunity (MESH:D020274), cardiac dysfunction (MESH:D006331), septic shock (MESH:D012772), bleeding (MESH:D006470), infection (MESH:D007239)
- **Chemicals:** lipids (MESH:D008055)
- **Species:** Nicotiana tabacum (American tobacco, species) [taxon 4097], Homo sapiens (human, species) [taxon 9606]

## Full text

_Full body text omitted from this summary view._ Fetch the complete paper as Markdown: https://tomesphere.com/paper/PMC13038030/full.md

## Figures

10 figures with captions in the complete paper: https://tomesphere.com/paper/PMC13038030/full.md

## References

55 references — full list in the complete paper: https://tomesphere.com/paper/PMC13038030/full.md

---
Source: https://tomesphere.com/paper/PMC13038030